These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 2947663)
21. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Edouard C; Vignon C; Mathieu L; Trechsel U Lancet; 1979 Sep; 2(8141):489-92. PubMed ID: 90215 [TBL] [Abstract][Full Text] [Related]
22. The effects of intravenous alendronate in Paget's disease of bone. O'Doherty DP; McCloskey EV; Vasikaran S; Khan S; Kanis JA J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285 [TBL] [Abstract][Full Text] [Related]
23. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389 [TBL] [Abstract][Full Text] [Related]
24. Comparison of methods of assessing response of Paget's disease to bisphosphonate therapy. Patel S; Coupland CA; Stone MD; Hosking DJ Bone; 1995 Feb; 16(2):193-7. PubMed ID: 7756047 [TBL] [Abstract][Full Text] [Related]
25. Comparative effects of an antiviral drug, inosiplex, and diphosphonates in Paget's disease of bone. Kanis JA; Preston CJ; Beard DJ; Beneton M; Harris S; Russell RG Bone; 1985; 6(2):69-72. PubMed ID: 2409999 [TBL] [Abstract][Full Text] [Related]
26. Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone. Heynen G; Delwaide P; Bijvoet OL; Franchimont P Eur J Clin Invest; 1982 Feb; 12(1):29-35. PubMed ID: 6802650 [No Abstract] [Full Text] [Related]
27. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907 [TBL] [Abstract][Full Text] [Related]
28. Bone scintigraphy following intravenous pamidronate for Paget's disease of bone. Ryan PJ; Gibson T; Fogelman I J Nucl Med; 1992 Sep; 33(9):1589-93. PubMed ID: 1517830 [TBL] [Abstract][Full Text] [Related]
29. Bisphosphonate resistance in Paget's disease of bone. Joshua F; Epstein M; Major G Arthritis Rheum; 2003 Aug; 48(8):2321-3. PubMed ID: 12905487 [TBL] [Abstract][Full Text] [Related]
30. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone. Cantrill JA; Buckler HM; Anderson DC Ann Rheum Dis; 1986 Dec; 45(12):1012-8. PubMed ID: 3813665 [TBL] [Abstract][Full Text] [Related]
31. Treatment of Paget's disease of bone with single dose intravenous pamidronate. Watts RA; Skingle SJ; Bhambhani MM; Pountain G; Crisp AJ Ann Rheum Dis; 1993 Aug; 52(8):616-8. PubMed ID: 8215628 [TBL] [Abstract][Full Text] [Related]
32. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study. Gutteridge DH; Retallack RW; Ward LC; Stuckey BG; Stewart GO; Prince RL; Kent GN; Bhagat CI; Price RI; Thompson RI; Nicholson GC Bone; 1996 Oct; 19(4):387-94. PubMed ID: 8894145 [TBL] [Abstract][Full Text] [Related]
33. Effects of disodium dichloromethylene diphosphonate (CL2MDP) on Paget's disease of bone. Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Vignon E; Trechsel U; Mathieu L; Edouard C Adv Exp Med Biol; 1980; 128():299-309. PubMed ID: 6448538 [No Abstract] [Full Text] [Related]
34. [The treatment of Paget's disease of bone with second-generation bisphosphonates via intravenous infusion]. Arboleya L; Sánchez J; Iglesias G; Arranz JL Rev Clin Esp; 1993 Dec; 193(9):467-71. PubMed ID: 8108576 [TBL] [Abstract][Full Text] [Related]
35. [Therapy of Paget's disease with bisphosphonate pamidronate (AHPrBP, formerly APD)]. Scharla SH; Grauer A; Ziegler R Klin Wochenschr; 1991 Jan; 69(1):25-30. PubMed ID: 2016845 [TBL] [Abstract][Full Text] [Related]
37. Treatment of Paget's bone disease with the bisphosphonate APD. Mautalen CA Henry Ford Hosp Med J; 1983; 31(4):244-8. PubMed ID: 6425243 [No Abstract] [Full Text] [Related]
38. Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate). Fraser TR; Ibbertson HK; Holdaway IM; Rutland M; King A; Dodd G; Wattie DJ Aust N Z J Med; 1984 Dec; 14(6):811-8. PubMed ID: 6442563 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of the bisphosphonate APD in the control of Paget's bone disease. Mautalen CA; Gonzalez D; Ghiringhelli G Bone; 1985; 6(6):429-32. PubMed ID: 4096879 [TBL] [Abstract][Full Text] [Related]
40. Determinants of remission of Paget's disease of bone. Patel S; Stone MD; Coupland C; Hosking DJ J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]